

EHMA 2024

Shaping and managing innovative health ecosystems

Health Technology Assessment of METAglut1™ test for the diagnosis of GLUT1 deficiency within pediatric setting

Lucrezia Bianca Ferrario

Università Carlo Cattaneo – LIUC

On behalf of Emanuela Foglia, Alessandra Bini, Andrea Paparelli, Nicoletta Bellato, Angelo Arcolini, Carlotta Lerda, Ilaria Robustino, Antonella Ciccarelli, Sara Olivotto, Pierangelo Veggiotti

5 - 7 June 2024 - Bucharest, Romania

Politehnica University of Bucharest, Bucharest, Romania

#EHMA2024

Relevance of the topic

Glucose transporter type 1 deficiency syndrome (GlutIDS) is a **rare genetic metabolic disorder** characterized impaired glucose transport across the blood-brain barrier leading to neurological deficits

EHMA 2024

- The rapid diagnosis is important to prevent GlutIDS complications: the ketogenic diet is highly effective in controlling the seizures and improving gait disturbance and is generally well tolerated
- The standard diagnostic procedure is represented by the **lumbar puncture**, an invasive procedure
- However, **most patients required genetic analysis**, with long reporting times, to confirm the diagnosis
- □ In this specific setting, METAglut1[™] emerged as an innovative in vitro diagnostic test, supporting Glut1DS diagnosis, giving a response within 24-72 hours

Despite its strategic and clinical relevance, no consensus exists in the Italian setting with regard its use in the clinical practice

Objective

To define the multidimensional impacts related to the implementation of the innovative blood test for GlutIDS diagnosis, in comparison to the standard diagnostic tools used to date in the Italian clinical practice, thus producing real-life information defining the test economic and organizational sustainability and supporting the development of an adequate reimbursement tariff The conduction of the HTA would be capable to answer to the following policy question: "<u>Which are the main benefits</u> <u>related to METAglut1™ for the diagnosis of</u> <u>Glut1DS, considering not only the hospital</u> <u>perspective, but also the clinical benefit</u> <u>for patients and potentially generalizable</u> <u>in the European context?"</u>

Methods

A Health Technology Assessment (HTA) analysis was performed, to bring together evidence and other relevant and reliable information for hospital managers to guide good investment decisions, within Glut1DS setting

HTA Core Model EUnetHTA

The Domains of the HTA Core Model®





Narrative literature review, to define efficacy and safety indicators, concerning the comparison of the traditional and the innovative diagnostic tools

Quantitative approach

Economic assessment of the patient diagnostic clinical pathways, considering METAglut1™ presence or absence, and conduction of a **budget** impact analysis to define METAglut1™ economic and financial sustainability



approach

EHMA 2024

Administration of specific qualitative questionnaires and interviews to healthcare professionals, examining their perceptions and acceptance in the conduction of the innovative diagnostic test

Results from the narrative literature review

Safety

	Technology			
Adverse events	Lumbar Puncture	Genetic Test	METAglut1™	
Headache	18% (p<0.05) (Ebinger & Rating, 2004)	/	/	
Back Pain	24% (p<0.001) (Ebinger & Rating, 2004)	/	/	
Nausea	23% (Ebinger & Rating, 2004)	/	/	




No impact on hospitals for the management of patients with the above adverse events

Efficacy

EHMA 2024

Literature declared that lumbar puncture and METAglut1[™] presents the same performances, in terms of sensibility and specificity

The difference emerged in the proportion of patients that could be tested, In terms of **% coverage of potentially**



Results from the economic analysis

The following 5 scenarios have been economically assessed and valorized: METAglut1™ test

- Patient with symptoms that can certainly be attributed to GLUT1 DS and is tested with traditional technology and thus tests positive
- 2) Patient with symptoms that can certainly be attributed to GLUT1 DS and is tested with traditional technology and thus tests negative, but with an in-depth test (MLPA) in order to confirm or not the negativity
- 3) Patient with symptoms that can not certainly be attributed to GLUT1 DS, and is not tested
- 4) Patient with symptoms that is tested with the innovative technology, thus tests positive and is also tested with the traditional technology in order to confirm the positivity
- 5) Patient with symptoms that is tested with the innovative technology, thus tests negative

Innovative situation: Presence of METAglut1™ *test* EHMA 2024

Absence of

Economic assessment of the process

🚹 Time Horizon: 12 months

Traditional situation	Patient's Pathway	%*	Economic evalution	
Tested patients	Patient's Pathway #1	35%	3,518.32 €	
	Patient's Pathway #2	5%	4,063.02 €	
Not tested patients	Patient's Pathway #3	60%	175.22 €	
Avera	ge weighted cost related to the traditional	situation	1,539.70 €	
Innovative situation	Patient's Pathway	%*	Economic evaluation	
		70		
Tested patients	Patient's Pathway #4	95%	5,286.63 €	
Tested patients				

*Distribution of patients by pathway is derived from expert opinion based on the current and observed clinical practice

Economic assessment of the process

Time Horizon: <u>8 years</u>

	%	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	Year 7	Total Costs	Average weighted cost
Patient's Pathway #1	40%	3,518.32 €	175.22 €	175.22 €	175.22 €	175.22 €	175.22 €	175.22 €	4,569.66 €	Traditional situation:
Patient's Pathway #2	5%	4,063.02 €	175.22 €	175.22 €	175.22 €	175.22 €	175.22 €	175.22 €	5,114.37 €	Absence of METAglut1™
Patient's Pathway #3	60%	175.22 €	175.22 €	175.22 €	3,518.32 €	175.22 €	175.22 €	175.22 €	4,569.66 €	test 4,596.90 €
Patient's Pathway #4	95%	5,286.63 €	175.22 €	175.22 €	175.22 €	175.22 €	175.22 €	175.22 €	6,337.98 €	Innovative situation: Presence
Patient's Pathway #5	5%	538.59€	175.22 €	175.22 €	175.22 €	175.22 €	175.22 €	175.22 €	1,589.93 €	of METAglut1™ test 6,100.58 €

Budget Impact Analysis

	Traditional Situation	Innovative Situation
Baseline Scenario	100%	0%
Scenario 1	80%	20%
Scenario 2	50%	50%
Scenario 3	20%	80%
Scenario 4	0%	100%



	Total costs	Difference (Euro)	Difference (%)
Baseline Scenario	307,939.52 €	0.00€	0.0%
Scenario 1	362,856.09 €	54,916.56 €	17.8%
Scenario 2	445,230.94 €	137,291.41 €	44.6%
Scenario 3	527,605.78 €	219,666.26 €	71.3%
Scenario 4	582,522.35 €	274,582.82 €	89.2%

EHMA 2024

~

From the economic assessment of the hospital costs to the economic assessment of the social costs

	Patient's Pathway #1	Patient's Pathway #2	Patient's Pathway #3	Patient's Pathway #4	/ Patient's Pathway #5
% tested patients	35%	5%	60% 95%		5%
Number of Hospital Accessed	5	6	2	6	4
Productivity loss related to the hospital accesses	425.00 €	510.00 €	170.00 €	510.00 €	340.00 €
Productivity loss related to the lumbar puncture	40.80 €	40.80 €		40.80 €	
Trasportation	75.00 €	90.00 €	30.00 €	90.00€	60.00 €
Drug (Levetiracetam doc 500 mg)		22.60 €*	452.04 €		452.04 €
Cognitive and behavioral support		90.00 €*	1,800.00 €		1,800.00 €
Social cost by patient's pathway	540.80€	753.40 €	2,452.04 €	640.80€	2,652.04€
Average weighted social cost		1,698.17 €			1.36 €
			- 5	6%	

Results from the healthcare professionals'

Dimensions	Standard Technology	Innovative Technology	
Safety	0.39	0.46	 □ No difference on the development of adverse events related to the procedure □ METAglut1[™] test is well tolerated
Effectiveness	-0,25	1.33	Higher and prompt GlutIDS detection rate
Equity impact	-0.17	-0.75	 Poor access to care on local level, due to the test's scarce availability Potential generation of health migrations phenomena
Social impact	-0.08	0.92	 Improved patients' and families' satisfaction Improved patients' quality of life Reduced social costs due to the diagnostic pathways
Legal impact	1.13	1.00	□ Need to regulate the acquisition of METAglut1 [™] test
Organizational impact	0.50	-1.25	 In the short term, training courses and hospital meetings are required for all the healthcare professionals involved, An improvement in the patient's clinical pathway may emerge

Conclusions

Results revealed **the potentialities of** METAglut1[™] in the improvement of the diagnostic pathway of such rare disease Healthcare **professionals** recognized benefits of METAglutI™ within all the HTA domains, thus declaring that its routinary use would optimize the overall patient management

EHMA 2024

Despite the need of additional investment that is absorbed in the long run given METAglut1[™] capability to modify the patients' pathway thanks to an accurate and prompt diagnosis, **a higher clinical benefit emerged with a consequent positive impact on the social point of view**

A real-life data collection would be required to make the results more robust and scalable, thus also considering a long-term time-horizon



EHMA 2024

Shaping and managing innovative health ecosystems

Thank you

Lucrezia Bianca Ferrario Università Carlo Cattaneo - LIUC <u>Iferrario@liuc.it</u>